Biotech

Inside the discoveries, personalities, and deals driving drug development. Sign up for the Readout newsletter here.

Amyloid-Plaques

In the Lab

Alzheimer’s and amyloid: ‘It’s time to do something else’

By Sharon Begley

Alzheimers hands

Biotech

After the blowup of the biggest hope for Alzheimer’s, what’s next in the pipeline?

By STAT staff

advertisement

Biotech

Alzheimer’s drug failure leaves Biogen in a precarious place

By Adam Feuerstein and Matthew Herper

advertisement

Biotech

Biogen halts studies of closely watched Alzheimer’s drug, a blow to hopes for new treatment

By Adam Feuerstein

Noubar Afeyan

Biotech

Flagship Pioneering raises $824 million in venture capital round, its most ever

By Jonathan Saltzman — Boston Globe

Mother and child

Biotech

FDA approves first new drug developed for women with postpartum depression

By Adam Feuerstein

Peggy Hamburg

In the Lab

World Health Organization advisers call for registry of studies on human genome editing

By Sharon Begley

advertisement

Vivek Ramaswamy Announcement

Biotech

Biotech’s brash entrepreneur finally finds drug-development success with overactive bladders

By Adam Feuerstein

advertisement

Emojis of the microbiome

Biotech

Investors have been snubbing the microbiome. That may be about to change

By Kate Sheridan

Dr. Steve Paul

Biotech

Biotech startup raises $68 million to further work on its treatment for schizophrenia

By Jonathan Saltzman — Boston Globe

Vascepa pill handout

Health

Amarin’s Vascepa prevents second and third heart attacks in analysis, fueling debate

By Matthew Herper

Clogged Artery

Biotech

New results show benefits of Esperion’s cholesterol drug — but leave big questions unanswered

By Matthew Herper

Medical syringe

Biotech

A Regeneron drug dominates eczema treatment. With new data, a small biotech believes it can compete

By Adam Feuerstein

Red blood cells

Biotech

Tiny PhaseBio gets the New England Journal’s spotlight. Can its shares rebound?

By Matthew Herper

Adam's Take

Cowen polled investors and doctors on the outlook for new biotech drugs. Here’s what they said

By Adam Feuerstein

The Readout LOUD

Listen: How startups stop, the new FDA boss, and Theranos on the big screen

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Overdrove the headlights

Biotech

‘We overdrove our headlights’: After his biotech startup fails, a CEO reflects on what went wrong

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Harvard

In the Lab

Hedge fund investing $100 million in Harvard drug research

By Jonathan Saltzman — Boston Globe

Theranos

Business

Documentarian Alex Gibney has taken on Enron, Scientology — and now Theranos

By Rebecca Robbins

A magnified view of C. difficile bacteria.

Biotech

Microbiome-based drugs likely to face FDA’s biologics pathway

By Kate Sheridan

Adam's Take

Taking the measure of small-cap biotech: Bio-Path Holdings, CytoDyn

By Adam Feuerstein

The Readout LOUD

Listen: Every conceivable angle of Scott Gottlieb’s FDA resignation

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Vials

Pharmalot

What’s in a name? FDA changes course for biosimilar names and upsets generic makers

By Ed Silverman

Scott Robinson

Biotech

It costs $4,600 a month to rent a lab bench here. For startups, it’s the place to be

By Jonathan Saltzman — Boston Globe

Alnylam headquarters

Biotech

Alnylam announces more positive data for a new RNAi drug candidate

By Kate Sheridan

STAT SPOTLIGHT

Biotech

Startup Spotlight: A Defense Department-backed biotech pushes platelets to clot blood

By Kate Sheridan

Scott Gottlieb shoes and socks

Politics

Scott Gottlieb’s sudden resignation will give biotech a panic attack

By Matthew Herper and Adam Feuerstein

Great Hall of the People in Beijing

Exclusive

China creating national medical ethics committee to oversee high-risk clinical trials

By Jane Qiu

Alkahest

Biotech

As the FDA warns against ‘young blood,’ an ambitious Silicon Valley startup tests a cocktail for Alzheimer’s

By Rebecca Robbins